J&J Touts New Product Strength In 2012 Year-End Call
This article was originally published in The Pink Sheet Daily
The global pharmaceutical giant has had several new products hit the market in the last two years that have allowed it to retain a global leadership position despite tough economic circumstances and issues with its consumer segment.
You may also be interested in...
The healthcare conglomerate reported strong sales in the first quarter that were largely due to growth of its pharmaceutical business, but got an extra boost from the continued renewal of its consumer products portfolio.
FDA approval of Zytiga in the pre-chemo setting gives the androgen blocker a second prostate cancer indication and another revenue stream – but a short remaining patent life and a significant competitive threat may mitigate the achievement.
In a conversation shortly before taking the helm at Johnson & Johnson, CEO Gorsky discusses deal strategies, emerging markets, his experience on both the device and pharma sides of the business, and opportunities for drug/device convergence.